BID

A novel BH3 domain-only death agonist

Kun Wang, Xiao-Ming Yin, Debra T. Chao, Curt L. Milliman, Stanley J. Korsmeyer

Research output: Contribution to journalArticle

745 Citations (Scopus)

Abstract

The BCL-2 family of proteins consists of both antagonists (e.g., BCL-2) and agonists (e.g., BAX) that regulate apoptosis and compete through dimerization. The BH1 and BH2 domains of BCL-2 are required to heterodimerize with BAX and to repress cell death; conversely, the BH3 domain of BAX is required to heterodimerize with BCL-2 and to promote cell death. To extend this pathway, we used interactive cloning to identity Bid, which encodes a novel death agonist that heterodimerizes with either agonists (BAX) or antagonists (BCL-2). BID possesses only the BH3 domain, lacks a carboxy- terminal signal-anchor segment, and is found in both cytosolic and membrane locations. BID counters the protective effect of BCL-2. Moreover, expression of BID, without another death stimulus, induces ICE-like proteases and apoptosis. Mutagenesis revealed that an intact BH3 domain of BID was required to bind the BH1 domain of either BCL-2 or BAX. A BH3 mutant of BID that still heterodimerized with BCL-2 failed to promote apoptosis, dissociating these activities. In contrast, the only BID BH3 mutant that retained death promoting activity interacted with BAX, but not BCL-2. This BH3-only molecule supports BH3 as a death domain and favors a model in which BID represents a death ligand for the membrane-bound receptor BAX.

Original languageEnglish (US)
Pages (from-to)2859-2869
Number of pages11
JournalGenes and Development
Volume10
Issue number22
StatePublished - 1996
Externally publishedYes

Fingerprint

Apoptosis
Cell Death
Caspase 1
Membranes
Dimerization
Mutagenesis
Organism Cloning
Ligands
Death Domain
Proteins

Keywords

  • Apoptosis
  • BCL-2 family
  • BH3 domain
  • BID
  • cysteine protease

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Cite this

Wang, K., Yin, X-M., Chao, D. T., Milliman, C. L., & Korsmeyer, S. J. (1996). BID: A novel BH3 domain-only death agonist. Genes and Development, 10(22), 2859-2869.

BID : A novel BH3 domain-only death agonist. / Wang, Kun; Yin, Xiao-Ming; Chao, Debra T.; Milliman, Curt L.; Korsmeyer, Stanley J.

In: Genes and Development, Vol. 10, No. 22, 1996, p. 2859-2869.

Research output: Contribution to journalArticle

Wang, K, Yin, X-M, Chao, DT, Milliman, CL & Korsmeyer, SJ 1996, 'BID: A novel BH3 domain-only death agonist', Genes and Development, vol. 10, no. 22, pp. 2859-2869.
Wang K, Yin X-M, Chao DT, Milliman CL, Korsmeyer SJ. BID: A novel BH3 domain-only death agonist. Genes and Development. 1996;10(22):2859-2869.
Wang, Kun ; Yin, Xiao-Ming ; Chao, Debra T. ; Milliman, Curt L. ; Korsmeyer, Stanley J. / BID : A novel BH3 domain-only death agonist. In: Genes and Development. 1996 ; Vol. 10, No. 22. pp. 2859-2869.
@article{bc652d7822fd44b4a90a10026c82cf70,
title = "BID: A novel BH3 domain-only death agonist",
abstract = "The BCL-2 family of proteins consists of both antagonists (e.g., BCL-2) and agonists (e.g., BAX) that regulate apoptosis and compete through dimerization. The BH1 and BH2 domains of BCL-2 are required to heterodimerize with BAX and to repress cell death; conversely, the BH3 domain of BAX is required to heterodimerize with BCL-2 and to promote cell death. To extend this pathway, we used interactive cloning to identity Bid, which encodes a novel death agonist that heterodimerizes with either agonists (BAX) or antagonists (BCL-2). BID possesses only the BH3 domain, lacks a carboxy- terminal signal-anchor segment, and is found in both cytosolic and membrane locations. BID counters the protective effect of BCL-2. Moreover, expression of BID, without another death stimulus, induces ICE-like proteases and apoptosis. Mutagenesis revealed that an intact BH3 domain of BID was required to bind the BH1 domain of either BCL-2 or BAX. A BH3 mutant of BID that still heterodimerized with BCL-2 failed to promote apoptosis, dissociating these activities. In contrast, the only BID BH3 mutant that retained death promoting activity interacted with BAX, but not BCL-2. This BH3-only molecule supports BH3 as a death domain and favors a model in which BID represents a death ligand for the membrane-bound receptor BAX.",
keywords = "Apoptosis, BCL-2 family, BH3 domain, BID, cysteine protease",
author = "Kun Wang and Xiao-Ming Yin and Chao, {Debra T.} and Milliman, {Curt L.} and Korsmeyer, {Stanley J.}",
year = "1996",
language = "English (US)",
volume = "10",
pages = "2859--2869",
journal = "Genes and Development",
issn = "0890-9369",
publisher = "Cold Spring Harbor Laboratory Press",
number = "22",

}

TY - JOUR

T1 - BID

T2 - A novel BH3 domain-only death agonist

AU - Wang, Kun

AU - Yin, Xiao-Ming

AU - Chao, Debra T.

AU - Milliman, Curt L.

AU - Korsmeyer, Stanley J.

PY - 1996

Y1 - 1996

N2 - The BCL-2 family of proteins consists of both antagonists (e.g., BCL-2) and agonists (e.g., BAX) that regulate apoptosis and compete through dimerization. The BH1 and BH2 domains of BCL-2 are required to heterodimerize with BAX and to repress cell death; conversely, the BH3 domain of BAX is required to heterodimerize with BCL-2 and to promote cell death. To extend this pathway, we used interactive cloning to identity Bid, which encodes a novel death agonist that heterodimerizes with either agonists (BAX) or antagonists (BCL-2). BID possesses only the BH3 domain, lacks a carboxy- terminal signal-anchor segment, and is found in both cytosolic and membrane locations. BID counters the protective effect of BCL-2. Moreover, expression of BID, without another death stimulus, induces ICE-like proteases and apoptosis. Mutagenesis revealed that an intact BH3 domain of BID was required to bind the BH1 domain of either BCL-2 or BAX. A BH3 mutant of BID that still heterodimerized with BCL-2 failed to promote apoptosis, dissociating these activities. In contrast, the only BID BH3 mutant that retained death promoting activity interacted with BAX, but not BCL-2. This BH3-only molecule supports BH3 as a death domain and favors a model in which BID represents a death ligand for the membrane-bound receptor BAX.

AB - The BCL-2 family of proteins consists of both antagonists (e.g., BCL-2) and agonists (e.g., BAX) that regulate apoptosis and compete through dimerization. The BH1 and BH2 domains of BCL-2 are required to heterodimerize with BAX and to repress cell death; conversely, the BH3 domain of BAX is required to heterodimerize with BCL-2 and to promote cell death. To extend this pathway, we used interactive cloning to identity Bid, which encodes a novel death agonist that heterodimerizes with either agonists (BAX) or antagonists (BCL-2). BID possesses only the BH3 domain, lacks a carboxy- terminal signal-anchor segment, and is found in both cytosolic and membrane locations. BID counters the protective effect of BCL-2. Moreover, expression of BID, without another death stimulus, induces ICE-like proteases and apoptosis. Mutagenesis revealed that an intact BH3 domain of BID was required to bind the BH1 domain of either BCL-2 or BAX. A BH3 mutant of BID that still heterodimerized with BCL-2 failed to promote apoptosis, dissociating these activities. In contrast, the only BID BH3 mutant that retained death promoting activity interacted with BAX, but not BCL-2. This BH3-only molecule supports BH3 as a death domain and favors a model in which BID represents a death ligand for the membrane-bound receptor BAX.

KW - Apoptosis

KW - BCL-2 family

KW - BH3 domain

KW - BID

KW - cysteine protease

UR - http://www.scopus.com/inward/record.url?scp=0029807585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029807585&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 2859

EP - 2869

JO - Genes and Development

JF - Genes and Development

SN - 0890-9369

IS - 22

ER -